03697nab a2200397 i 4500 publ28452 20240108103936.0 231018s2024 hu o 0|| Angol d 0003-4967 10.1136/ard-2023-224762 doi 34193576 mtmt SZTE Publicatio Repozitórium hun Angol Fanouriakis Antonis EULAR recommendations for the management of systemic lupus erythematosus [elektronikus dokumentum] : 2023 update / Fanouriakis Antonis 2024 15-29 ANNALS OF THE RHEUMATIC DISEASES 83 No. 1 To update the EULAR recommendations for the management of systemic lupus erythematosus (SLE) based on emerging new evidence.An international Task Force formed the questions for the systematic literature reviews (January 2018-December 2022), followed by formulation and finalisation of the statements after a series of meetings. A predefined voting process was applied to each overarching principle and recommendation. Levels of evidence and strengths of recommendation were assigned, and participants finally provided their level of agreement with each item.The Task Force agreed on 5 overarching principles and 13 recommendations, concerning the use of hydroxychloroquine (HCQ), glucocorticoids (GC), immunosuppressive drugs (ISDs) (including methotrexate, mycophenolate, azathioprine, cyclophosphamide (CYC)), calcineurin inhibitors (CNIs, cyclosporine, tacrolimus, voclosporin) and biologics (belimumab, anifrolumab, rituximab). Advice is also provided on treatment strategies and targets of therapy, assessment of response, combination and sequential therapies, and tapering of therapy. HCQ is recommended for all patients with lupus at a target dose 5 mg/kg real body weight/day, considering the individual's risk for flares and retinal toxicity. GC are used as 'bridging therapy' during periods of disease activity; for maintenance treatment, they should be minimised to equal or less than 5 mg/day (prednisone equivalent) and, when possible, withdrawn. Prompt initiation of ISDs (methotrexate, azathioprine, mycophenolate) and/or biological agents (anifrolumab, belimumab) should be considered to control the disease and facilitate GC tapering/discontinuation. CYC and rituximab should be considered in organ-threatening and refractory disease, respectively. For active lupus nephritis, GC, mycophenolate or low-dose intravenous CYC are recommended as anchor drugs, and add-on therapy with belimumab or CNIs (voclosporin or tacrolimus) should be considered. Updated specific recommendations are also provided for cutaneous, neuropsychiatric and haematological disease, SLE-associated antiphospholipid syndrome, kidney protection, as well as preventative measures for infections, osteoporosis, cardiovascular disease.The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion. Klinikai orvostan Kostopoulou Myrto aut Andersen Jeanette aut Aringer Martin aut Arnaud Laurent aut Bae Sang-Cheol aut Boletis John aut Bruce Ian N. aut Cervera Ricard aut Doria Andrea aut Dörner Thomas aut Furie Richard A. aut Kovács László aut Nagy György aut et al. aut http://publicatio.bibl.u-szeged.hu/28452/3/34193576_megjelent.pdf Dokumentum-elérés http://publicatio.bibl.u-szeged.hu/28452/1/EULAR2023update.pdf Dokumentum-elérés